Please use this identifier to cite or link to this item: https://dora.health.qld.gov.au/qldresearchjspui/handle/1/11278
Title: Cefazolin for Methicillin-Susceptible Staphylococcus aureus Bacteremia
Authors: Lee, Todd C.;Barina, Lauren A.;Walls, Genevieve;Goodman, Anna L.;Yahav, Dafna;Cheng, Matthew P.;Bonten, Marc;Bowen, Asha C.;Boyles, Tom;Daneman, Nick;Ekkelenkamp, Miquel B.;Rennert-May, Elissa;Richards, Alexander J.;Rogers, Benjamin A.;Sahng, Euna;Salada, Brenda;Scheuerman, Oded;Schneider, Kellie;Schulz, Thomas R.;Schwartz, Kevin L.;McDonald, Emily G.;Giulieri, Stefano G.;Simos, Peter A.;Singh, Harsimran;Sinkeler, Fleur S.;Smith, Simon ;Smith, Benjamin J.;Smith, Stephanie W.;Somayaji, Ranjani;Sommerville, Christine;Song, Rima X. J.;Sowden, David C.;Goulding, Susan R.;McKew, Genevieve;Stark, Michael J.;Stone, Neil R. H.;Strunk, Tobias;Sud, Archana;Swe, Khine P.;Symons, Caitlin R.;Tan, Yen Ee;Ten Doesschate, Thijs;Thien, Siew Yee;Grant, Jennifer M.;Thomas, Ashmitha;McLean, Alistair R. D.;Trad, Mohamad-Ali;Tramontana, Adrian R.;Tsang, Jennifer L. Y.;Ulett, Kimberly;Underwood, Jonathan;van Welzen, Berend J.;Vazquez-Grande, Gloria;Velasquez Reyes, Diana C.;Gregson, Daniel;Verberk, Janneke D. M.;Voss, Lesley M.;McMullan, Brendan J.;Ward, Denise;Webb, Rachel H.;Whitmore, Timothy J.;Wieder-Finesod, Anat;Wilson, Heather L.;Wilson, Evan W.;Wong, Hei Man;Grimwade, Kate C.;Wong She, Kate;Wuerz, Terence;Yamamura, Deborah L.;McQuilten, Zoe K.;Yeoh, Alastair;Yow, Boris Long Hei;Dymock, Michael;Mahar, Robert K.;McGlothlin, Anna;Marsh, Julie A.;Grupper, Mordechai;Davis, Joshua S.;Tong, Steven Y. C. ;Staphylococcus aureus Network Adaptive Platform Trial, Group;Morpeth, Susan C.;Paterson, David L.;Roberts, Jason A.;Robinson, J. Owen;Saito, Hiroki;Scarborough, Matthew;Ten Oever, Jaap;Guy, Stephen D.;Turner, Rebecca M.;Tverring, Jonas;van Hal, Sebastiaan J.;Webb, Steve A.;Whiteway, Lynda M.;Arias, Cesar A.;Henderson, Andrew ;Heriot, George S.;Snelling, Tom L.;Afra, Kevin;Gwee, Amanda;Ali, Shabinah S.;Amit, Sharon;Anagnostou, Nicholas A.;Archuleta, Sophia;Aston, Stephen J.;Athan, Eugene;Baharav, Nadav;Bai, Anthony D.;Barber, Bridget E.;Baskaran, Abinayah;Hall, Victoria G.;Berkeley, Michelle M. A.;Best, Emma J.;Bhilave, Nilesh R.;Bloomfield, Max G.;Bond, Katherine A.;Bostock, Jennifer;Botheras, Carly L.;Boyd, Mark A.;Bradshaw, Sophia M. E.;Briggs, Elizabeth J.;Hardy, Erica J.;Britton, Philip N.;Campbell, Anita J.;Carr, Beau Z.;Chancellor, James A.;Chen, Kevin;Cheong, Elaine Y.;Chew, Ka Lip;Chia, Po Ying;Chomba, Rispah;Chong, Brian S. W.;Ghanem-Zoubi, Nesrin;Clews, Chris J. N.;Cohen, Jonathan M.;Commons, Robert J.;Cutfield, Tim;Daley, Peter;Daniel, Diane S.;Davies, Jane;De, Partha;Denholm, Justin T.;Di Virgilio, Mia;Harris, David J.;Dishon-Benattar, Yael;Dotel, Ravindra;Duan, Erick H.;Easom, Nicholas;Eliakim-Raz, Noa;England, Michelle M.;Fahmy, Mark ;Findlater, Aidan R.;Flanagan, Katie L.;Foo, Ethan Z. J.;Hatcher, James;Foo, Hong;Forster, Daniel P.;Fralick, Michael;Frazer, Jaimie L.;Gador-Whyte, Andrew P.;Garnham, Katherine;German, Greg J.;Ghosh, Niladri;Gisolf, Elisabeth H.;Hobbs, Mark R.;Holmes, Natasha E.;Howden, Benjamin P.;Huggan, Paul J.;Jennings, Zoe A.;Johnstone, Jennie;Juniper, Thomas;Kalimuddin, Shirin;Hensgens, Marjolein P. M.;Kamfose, Musaiwale;Kandel, Christopher;Kelly, Matthew J.;Kozak, Robert A.;Kümin, Michelle;Lamontagne, Francois;Lau, Jillian S. Y.;Lee, Ivor Russel;Lin, Ray J.;Lindsay, Daisy;Jager, Nynke G. L.;Llewelyn, Martin J.;Longtin, Yves;Lother, Sylvain A.;Luey, Christopher E.;MacFadden, Derek R.;Mahony, Andrew A.;Malden, Catherine;Malhamé, Isabelle;Manning, Laurens A.;Marks, Michael ;Kaasch, Achim J.;Martin, Leslie J.;Matthews, Gail V.;McGann, Patrick H.;McMahon, James H.;Melon, Alexandra;Menon, Vidthiya;Mertz, Dominik;Meyer, Michael P.;Molton, James S.;Mora, Jocelyn M.;Kouijzer, Ilse J. E.;Moran, Ed;Mortimer, Leanne M.;Motaganahalli, Satwik;Muller, Matthew P.;Munro, Alasdair P. S.;Murray, Fionnuala A.;Murthy, Srinivas;Nagendra, Vanathi;Nel, Henco;New, David W. J.;Lewis, Roger J.;Nguyen, Vi;Norton, Grace;Norton, Katherine M.;Nourse, Clare B.;Nye, Clemency J. S.;O'Callaghan, Kevin ;O'Sullivan, Matthew V. N.;Ong, Sean W. X.;Otu, Akaninyene A.;Owen, Melissa;Lumley, Thomas;Papenburg, Jesse;Parkes, Leighanne O.;Paul, Mical;Perez-Patrigeon, Santiago;Petersiel, Neta;Petrella, Lina;Pett, Sarah L.;Pham, David;Piazzese, Chiara J.;Poulin, Sebastien;Lye, David C.;Rehak, Renata
Issue Date: 2026
Source: Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Group; Lee TC, Barina LA, Walls G, Goodman AL, Yahav D, Cheng MP, Bonten M, Bowen AC, Boyles T, Daneman N, Ekkelenkamp MB, Ghanem-Zoubi N, Hensgens MPM, Jager NGL, Kaasch AJ, Kouijzer IJE, Lewis RJ, Lumley T, Lye DC, McDonald EG, McKew G, McLean ARD, McMullan BJ, McQuilten ZK, Morpeth SC, Paterson DL, Roberts JA, Robinson JO, Saito H, Scarborough M, Ten Oever J, Turner RM, Tverring J, van Hal SJ, Webb SA, Whiteway LM, Arias CA, Henderson A, Heriot GS, Snelling TL, Afra K, Ali SS, Amit S, Anagnostou NA, Archuleta S, Aston SJ, Athan E, Baharav N, Bai AD, Barber BE, Baskaran A, Berkeley MMA, Best EJ, Bhilave NR, Bloomfield MG, Bond KA, Bostock J, Botheras CL, Boyd MA, Bradshaw SME, Briggs EJ, Britton PN, Campbell AJ, Carr BZ, Chancellor JA, Chen K, Cheong EY, Chew KL, Chia PY, Chomba R, Chong BSW, Clews CJN, Cohen JM, Commons RJ, Cutfield T, Daley P, Daniel DS, Davies J, De P, Denholm JT, Di Virgilio M, Dishon-Benattar Y, Dotel R, Duan EH, Easom N, Eliakim-Raz N, England MM, Fahmy M, Findlater AR, Flanagan KL, Foo EZJ, Foo H, Forster DP, Fralick M, Frazer JL, Gador-Whyte AP, Garnham K, German GJ, Ghosh N, Gisolf EH, Giulieri SG, Goulding SR, Grant JM, Gregson D, Grimwade KC, Grupper M, Guy SD, Gwee A, Hall VG, Hardy EJ, Harris DJ, Hatcher J, Hobbs MR, Holmes NE, Howden BP, Huggan PJ, Jennings ZA, Johnstone J, Juniper T, Kalimuddin S, Kamfose M, Kandel C, Kelly MJ, Kozak RA, Kümin M, Lamontagne F, Lau JSY, Lee IR, Lin RJ, Lindsay D, Llewelyn MJ, Longtin Y, Lother SA, Luey CE, MacFadden DR, Mahony AA, Malden C, Malhamé I, Manning LA, Marks M, Martin LJ, Matthews GV, McGann PH, McMahon JH, Melon A, Menon V, Mertz D, Meyer MP, Molton JS, Mora JM, Moran E, Mortimer LM, Motaganahalli S, Muller MP, Munro APS, Murray FA, Murthy S, Nagendra V, Nel H, New DWJ, Nguyen V, Norton G, Norton KM, Nourse CB, Nye CJS, O'Callaghan K, O'Sullivan MVN, Ong SWX, Otu AA, Owen M, Papenburg J, Parkes LO, Paul M, Perez-Patrigeon S, Petersiel N, Petrella L, Pett SL, Pham D, Piazzese CJ, Poulin S, Rehak R, Rennert-May E, Richards AJ, Rogers BA, Sahng E, Salada B, Scheuerman O, Schneider K, Schulz TR, Schwartz KL, Simos PA, Singh H, Sinkeler FS, Smith S, Smith BJ, Smith SW, Somayaji R, Sommerville C, Song RXJ, Sowden DC, Stark MJ, Stone NRH, Strunk T, Sud A, Swe KP, Symons CR, Tan YE, Ten Doesschate T, Thien SY, Thomas A, Trad MA, Tramontana AR, Tsang JLY, Ulett K, Underwood J, van Welzen BJ, Vazquez-Grande G, Velasquez Reyes DC, Verberk JDM, Voss LM, Ward D, Webb RH, Whitmore TJ, Wieder-Finesod A, Wilson HL, Wilson EW, Wong HM, Wong She K, Wuerz T, Yamamura DL, Yeoh A, Yow BLH, Dymock M, Mahar RK, McGlothlin A, Marsh JA, Davis JS, Tong SYC. Cefazolin for Methicillin-Susceptible Staphylococcus aureus Bacteremia. N Engl J Med. 2026 Jun 18;394(23):2329-2339. doi: 10.1056/NEJMoa2506905. PMID: 42308484; PMCID: PMC7619232.
Pages: 2329-2339
Journal Title: The New England journal of medicine
Abstract: Background Staphylococcus aureus bacteremia is associated with high mortality. Whether cefazolin or an antistaphylococcal penicillin should be preferred for the treatment of methicillin-susceptible S. aureus bacteremia is unclear. Methods In an ongoing international Bayesian adaptive platform trial, we conducted an open-label, randomized comparison of cefazolin with an antistaphylococcal penicillin (flucloxacillin or cloxacillin) in adult patients with penicillin-resistant, methicillin-susceptible S. aureus bacteremia. The primary outcome, which was evaluated with a hierarchical Bayesian logistic-regression model, was death from any cause within 90 days after enrollment in the platform. We assessed the posterior probability of the noninferiority of cefazolin to flucloxacillin or cloxacillin (with the criterion for noninferiority prespecified as an adjusted odds ratio of <1.2, which approximates an absolute difference in mortality of <2.5 percentage points if mortality in the antistaphylococcal-penicillin group is 15%), as well as the posterior probability of superiority (with the criterion of an adjusted odds ratio of <1.0). Secondary safety outcomes included the development of acute kidney injury within 14 days. Results This domain of the ongoing trial was conducted between February 17, 2022, and August 7, 2024, by which time the criterion for noninferiority had been met. Mortality at 90 days among adults who could be evaluated was 15.0% (97 deaths among 645 patients) in the cefazolin group and 17.0% (109 deaths among 642 patients) in the antistaphylococcal-penicillin group (adjusted odds ratio, 0.81; 95% credible interval, 0.59 to 1.12; probability of noninferiority, 99.2%; probability of superiority, 89.8%). Acute kidney injury occurred in 92 of 660 patients (13.9%) in the cefazolin group, as compared with 127 of 648 (19.6%) in the antistaphylococcal-penicillin group (adjusted odds ratio, 0.67; 95% credible interval, 0.50 to 0.89; probability of superiority, 99.7%). Conclusions In patients with methicillin-susceptible S. aureus bacteremia, cefazolin was noninferior to flucloxacillin or cloxacillin with respect to 90-day mortality and was associated with a lower incidence of acute kidney injury. (Funded by the National Health and Medical Research Council and others; SNAP ClinicalTrials.gov number, NCT05137119.).
Description: Cairns & Hinterland Hospital and Health Service (CHHHS) affiliated author: Simon Smith
DOI: 10.1056/NEJMoa2506905
Type: Journal article
Appears in Sites:Cairns & Hinterland HHS Publications
Queensland Health Publications

Show full item record

Page view(s)

770
checked on Nov 19, 2026

Google ScholarTM

Check

Altmetric


Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.